Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 184

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 184
---
ifying Officers conducted
a review of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act, Rules 13a-15(e) and
15-d-15(e)) as of the end of the period covered by this Annual Report (the “Evaluation Date”). Based upon that evaluation,
the Certifying Officers concluded that, as of June 30, 2024, our disclosure controls and procedures were not effective in ensuring that
the information we were required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended,
is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms.

Management Annual Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control
over financial reporting for the Company. Management used the “Internal Control over Financial Reporting Integrated Framework”
issued by the Committee of Sponsoring Organizations (“COSO-2013”) to conduct a review of the Company’s internal controls
over financial reporting. As of June 30, 2024, Management concluded that internal controls over financial reporting were not effective,
based on COSO’s framework. The deficiency is attributed to the Company not having adequate resources to address complex accounting
matters. This control deficiency will be monitored, and attention will be given to this matter as the Company grows.

This Annual Report does not include
an attestation report from the Company’s registered public accounting firm regarding internal controls over financial reporting.
Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the rules
of the SEC that permit the Company to provide only management’s report in this Annual Report.

Changes in Internal Control over Financial Reporting

There were no changes in our internal
control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.

<div align='center'>71</div>

Item 9B. Other Information

During the Company’s fourth quarter, no director or officer adopted or terminated a
Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.

<div align='center'>PART III</div>

Item 10. Directors, Executive Officers and Corporate Governance

The information
required by this Item 10 is included under the corresponding item number of Amendment No. 1 on Form 10-K/A as filed with the Securities
and Exchange Commission on